Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.09. | Nasdaq Stockholm AB: New equity right for trading, Gabather TO 6 | 231 | GlobeNewswire | At the request of Gabather AB, equity rights TO 6 will be traded on First North
Growth Market as from 5 September 2024.
Security name: Gabather TO 6
-----------------------------
Short name: GABA... ► Artikel lesen | |
19.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 19.07.2024 | 399 | Xetra Newsboard | Das Instrument D7GA US64026Q1085 NEL ASA ADR/30 NK -,20 EQUITY wird cum Kapitalmassnahme gehandelt am 19.07.2024 und ex Kapitalmassnahme am 22.07.2024 The instrument D7GA US64026Q1085 NEL ASA ADR/30... ► Artikel lesen | |
10.04. | Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002 | 313 | PR Newswire | STOCKHOLM, April 10, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the Centre for Neuropsychiatric... ► Artikel lesen | |
18.03. | Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders | 286 | PR Newswire | STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the... ► Artikel lesen | |
07.03. | Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study | 269 | PR Newswire | STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded... ► Artikel lesen | |
GABATHER Aktie jetzt für 0€ handeln | |||||
15.01. | Nasdaq Stockholm AB: New equity right for trading, Gabather TO 5 (24/24) | 458 | GlobeNewswire | At the request of Gabather AB, equity rights TO 5 will be traded on First North
as from 16 January 2024.
Security name: Gabather TO 5
-----------------------------
Short name: GABA TO 5
-----------------------------
ISIN... ► Artikel lesen | |
09.01. | Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Gabather AB (publ) (12/24) | 359 | GlobeNewswire | Trading in Gabather AB paid subscription units is to cease. The last trading
day is January 10, 2024.
Short name: GABA BTU
ISIN code: SE0021149721
Orderbook ID: 313990
This information is distributed... ► Artikel lesen | |
05.12.23 | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Gabather AB (633/23) | 506 | GlobeNewswire | With effect from December 06, 2023, the unit rights in Gabather AB will be
traded on First North Growth Market. Trading will continue up until and
including December 15, 2023.
Instrument: Unit rights... ► Artikel lesen | |
28.11.23 | Nasdaq Stockholm AB: Gabather AB receives observation status (606/23) | 446 | GlobeNewswire | Yesterday, on November 27, 2023, Gabather AB (the "Company") disclosed its
interim report for the third quarter of 2023 with information on the Company's
financial situation.
The rules of Nasdaq First... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MERCK KGAA | 138,10 | 0,00 % | DAX-Check LIVE: Adesso, Bilfinger, Cewe, E.ON, K+S, Merck, ProSieben, Siemens, SMA, Telekom & Co. | Der DAX testete gestern die 19.000 Punkte-Marke. Im Tagestief fiel er bis auf 18.838 Zähler. Eine Stunde vor Handelsschluss setzte dann aber eine Erholung ein. Das Minus betrug schließlich nur noch... ► Artikel lesen | |
GSK | 15,765 | -0,28 % | Dividendenbekanntmachungen (14.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PROPERTY INCOME TRUST LIMITED GB0033875286 0,003 GBP 0,0036 EUR AFFILIATED MANAGERS GROUP INC US0082521081 0,01 USD 0,0094... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 423,75 | -1,03 % | VERTEX - Wie kurz sind die Beine politischer Börsen? | ||
BAUSCH HEALTH | 7,869 | +1,20 % | Bausch Health Companies Inc.: Bausch Health and Salix to Present at the American Association for the Study of Liver Disease the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis | Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)... ► Artikel lesen | |
ALNYLAM PHARMACEUTICALS | 235,90 | -0,08 % | Alnylam Presents New Phase 1 Results For Next-Gen RNAi Therapy Nucresiran In ATTR Amyloidosis | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), a next-generation RNAi therapy being... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 0,933 | -2,25 % | Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence | - NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -
SAN FRANCISCO, Nov. 18,... ► Artikel lesen | |
APONTIS PHARMA | 9,740 | -1,62 % | Apontis Pharma: "Wir haben unsere Hausaufgaben gemacht" | Zentiva bietet den Aktionären der Apontis Pharma im Rahmen eines öffentlichen Erwerbsangebots einen Betrag von 10,00 Euro je Aktie. Vorstand und Aufsichtsrat von Apontis Pharma halten den Angebotspreis... ► Artikel lesen | |
MEDPACE | 314,40 | +1,58 % | Medpace Holdings, Inc. Reports Third Quarter 2024 Results | CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Results
Revenue... ► Artikel lesen | |
CANTOURAGE GROUP | 4,480 | -1,75 % | EQS-News: Cantourage Group SE: Neuer Umsatzrekord: Cantourage Group SE erzielt EUR 5,5 Mio. Umsatz im Oktober 2024 und bestätigt Wachstumsziele für das Gesamtjahr | EQS-News: Cantourage Group SE
/ Schlagwort(e): Umsatzentwicklung/Monatszahlen
Neuer Umsatzrekord: Cantourage Group SE erzielt EUR 5,5 Mio. Umsatz im Oktober 2024 und bestätigt... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | -100,00 % | TITAN PHARMACEUTICALS INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
SCYNEXIS | 1,110 | -1,33 % | SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to... ► Artikel lesen | |
INVENTIVA | 2,530 | -2,32 % | INVENTIVA: Statement of total voting rights and shares forming the company's share capital as of November 4, 2024 | Article R. 22-10-23 of the French Commercial Code
Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com
Date Number of Shares Outstanding Total voting... ► Artikel lesen | |
CHAMPIONS ONCOLOGY | 3,980 | -4,78 % | Champions Oncology, Inc.: Champions Oncology Announces Agreement with Weill Cornell Medicine | HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement... ► Artikel lesen | |
BAYER | 19,330 | -1,10 % | Buy or Goodbye?: Die Analystenstimmen des Tages: Infineon, Bayer, DHL Group und Jenoptik | © Foto: Oliver Berg/dpaGoldman Sachs senkt das Kursziel für Bayer und UBS senkt das Kursziel für Infineon. Unterdessen wird Barclays bei der Aktie DHL Group zurückhaltender.Goldman Sachs senkt das Kursziel... ► Artikel lesen | |
NOVO NORDISK | 97,07 | -2,93 % | Die Anleger von Moderna zittern vor Robert F. Kennedy, auch BioNTech gerät unter Druck, Pfizer folgt dem Beispiel und Novo Nordisk bekommt es mit immer mehr Konkurrenz zu tun | Rund zwei Monate vor dem Amtsantritt von Donald Trump nimmt dessen Kabinett langsam Formen an. Die Presse findet für die bisherigen Entscheidungen illustre Worte, sehr beliebt ist etwa das "Gruselkabinett".... ► Artikel lesen |